Clinical applications of fluorodeoxyglucose-positron emission tomography in the management of malignant melanoma

Current Opinion in Oncology

Volumn 17, Issue 2, 2005, Pages 154-159

  Kumar, Rakesh ^a   Alavi, Abass ^b  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Fluorodeoxyglucose positron emission tomography; Malignant melanoma; Oncology; Sentinel lymph node

Indexed keywords

FLUORODEOXYGLUCOSE;

ABDOMINAL CANCER; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG METABOLISM; DRUG UPTAKE; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; LUNG METASTASIS; LUNG NODULE; LYMPH NODE METASTASIS; MELANOMA; NON INVASIVE MEASUREMENT; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE; SKIN METASTASIS; TREATMENT PLANNING; TUMOR VOLUME;

FLUORODEOXYGLUCOSE F18; HUMANS; MELANOMA; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SKIN NEOPLASMS;

EID: 17144373700     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000152626.98124.3a     Document Type: Review

References (37)

1. Cancer facts & figures 2004, in American Cancer Society, surveillance research. Atlanta, Georgia: American Cancer Society; 2004.
2. Kalady MF, White RR, Johnson JL. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg 2003; 238:528-535, discussion 535-537.
3. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factor analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-3634.
4. Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; 30(Suppl 1):S42-S55.
5. Wahl RL, Kaminski MS, Ethier SP, Hutchins GD. The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 1990; 31:1831-1835.
6. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:976-983.
7. Topping A, Dewar D, Rose V, et al. Five years of sentinel node biopsy for melanoma: the St George's Melanoma Unit experience. Br J Plast Surg 2004; 57:97-104. This is a nice paper that demonstrates the accuracy of sentinel node biopsy and its role as a prognostic indicator in a large number of patients at a single center.
8. Blessing C, Feine U, Geiger L, et al. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 1995; 131:1394-1398.
9. Wagner JD, Schauwecker D, Hutchins G, Goleman JJ 3rd. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997; 64:181-189.
10. Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998; 16:1770-1776.
11. Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999; 17:1508-1515.
12. Crippa F, Leutner M, Belli F, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000; 41:1491-1494.
13. Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous melanoma. J Clin Oncol 2001; 19:2674-2678.
14. Havenga K, Cobben DC, Oyen WJ, et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 2003; 29:662-664.
15. Longo MI, Lazaro P, Bueno C, et al. Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol Surg 2003; 29:245-248.
16. Fink AM, Holle-Robatsch S, Herzog N, et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res 2004; 14:141-145.
17. Hafner J, Schmid MH, Kempf W, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol 2004; 150:677-686. This is an interesting study in which authors concluded that the value of whole body staging at baseline remains limited.
18. Klein M, Freedman N, Lotem M, et al. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma: a pilot study. Nuklearmedizin 2000; 39:56-61.
19. Wagner JD, Schauwecker DS, Davidson D, et al. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001; 77:237-242.
20. Schwimmer J, Essner R, Patel A, et al. A review of the literature for wholebody FDG PET in the management of patients with melanoma. Q J Nucl Med 2000; 44:153-167.
21. Krug B, Dietlein M, Groth W, et al. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods. Acta Radiol 2000; 41:446-452.
22. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993; 34:1420-1427.
23. Steinert HC, Huch Boni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D- glucose. Radiology 1995; 195:705-709.
24. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996; 6:325-329.
25. Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82:1664-1671.
26. Holder WD Jr, White RL Jr, Zuger JH, et al. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998; 227:764-769.
27. Eigtved A, Andersson AP, Dahlstrom K, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000; 27:70-75.
28. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000; 89:1019-1025.
29. Acland KM, O'Doherty MJ, Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol 2000; 42:606-611.
30. Swetter SM, Carroll LA, Johnson DL, Segall GM. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 2002; 9:646-653.
31. Finkelstein SE, Carrasquillo JA, Hoffman JM, et al. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol 2004; 11:731-738. A recent study evaluating the added value of FDG-PET over conventional imaging in stage IV melanoma patients undergoing metastasectomy.
32. Stas M, Stroobants S, Dupont P, et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 2002; 12:479-490.
33. Mijnhout GS, Comans EF, Raijmakers P, et al. Reproducibility and clinical value of 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma. Nucl Med Commun 2002; 23:475-481.
34. Fuster D, Chiang S, Johnson G, et al. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 2004; 45:1323-1327. A recent study comparing PET and conventional imaging in detecting locoregional disease and distant metastases.
35. Jadvar H, Johnson DL, Segall GM. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med 2000; 25:48-51.
36. Wong C, Silverman DH, Seltzer M, et al. The impact of 2-deoxy-2[18F] fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: the referring physician's perspective. Mol Imaging Biol 2002; 4:185-190.
37. Gulec SA, Faries MB, Lee CC, et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med 2003; 28:961-965.